ES (S&P 500) S&P 500 correction is over. We not only managed to make ...
The American manufacturer of equipment for the medical sector and consumables, Becton Dickinson, reported for the IV fiscal quarter of 2022, which ended in September.
There are both impressive moments and aspects that are worth paying attention to as a precaution.
Strengths of reporting:
Nuances that may further matter:
Becton Dickinson starts its fiscal year ahead of competitors – Abbott and Thermo Fisher – and reduces revenue expectations from the sale of tests to $125 million from $175 million for the fiscal year 2022. In fiscal year 2021, test sales brought the company $511 million.
In general, Becton Dickinson’s positions look quite strong.
At the moment, the consensus forecast for the company’s shares assumes a mark of $300 by June 2023.
On the daily trading chart of Becton Dickinson shares, the MACD indicator is growing in the negative zone and forms a buy signal. The Stochastic oscillator remains in the positive zone and holds the buy signal in force.